ATE533783T1 - Potente und selektive mittlersubstanzen von cholesterolefflux - Google Patents

Potente und selektive mittlersubstanzen von cholesterolefflux

Info

Publication number
ATE533783T1
ATE533783T1 AT07874411T AT07874411T ATE533783T1 AT E533783 T1 ATE533783 T1 AT E533783T1 AT 07874411 T AT07874411 T AT 07874411T AT 07874411 T AT07874411 T AT 07874411T AT E533783 T1 ATE533783 T1 AT E533783T1
Authority
AT
Austria
Prior art keywords
cholesterolefflux
potent
polypeptides
apo
parallels
Prior art date
Application number
AT07874411T
Other languages
English (en)
Inventor
John K Bielicki
Jan Johansson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE533783T1 publication Critical patent/ATE533783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07874411T 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux ATE533783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
ATE533783T1 true ATE533783T1 (de) 2011-12-15

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07874411T ATE533783T1 (de) 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux

Country Status (10)

Country Link
US (1) US8987192B2 (de)
EP (1) EP2121746B1 (de)
JP (1) JP2010513311A (de)
CN (1) CN101675072A (de)
AT (1) ATE533783T1 (de)
AU (1) AU2007349237B2 (de)
CA (1) CA2672131C (de)
DK (1) DK2121746T3 (de)
ES (1) ES2377329T3 (de)
WO (1) WO2008115303A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102123722A (zh) 2008-06-18 2011-07-13 加利福尼亚大学董事会 改进的胆固醇流出的肽介质
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ATE387459T1 (de) * 2000-04-06 2008-03-15 Kos Pharma Inc Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
EP1706131A4 (de) 2003-12-15 2009-08-12 Univ California Den zellulären cholesterin-efflux stimulierende helikale synthetische peptide
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質ａ１の模倣物とその使用
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Also Published As

Publication number Publication date
WO2008115303A2 (en) 2008-09-25
CA2672131C (en) 2016-06-07
US8987192B2 (en) 2015-03-24
EP2121746B1 (de) 2011-11-16
ES2377329T3 (es) 2012-03-26
HK1138292A1 (en) 2010-08-20
WO2008115303A3 (en) 2008-12-24
AU2007349237A1 (en) 2008-09-25
AU2007349237B2 (en) 2014-01-23
US20120329703A1 (en) 2012-12-27
CA2672131A1 (en) 2008-09-25
EP2121746A2 (de) 2009-11-25
CN101675072A (zh) 2010-03-17
DK2121746T3 (da) 2012-03-05
JP2010513311A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
WO2009155366A3 (en) Improved peptide mediators of cholesterol efflux
DK2121746T3 (da) Potente og selektive mediatorer af kolesterolefflux
DE60219419D1 (de) Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
NO20073981L (no) Criptobindende molekyler
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
WO2005095457A3 (en) Immunoglobulins
WO2007135571A3 (en) Blood group antigens of different types for diagnostic and therapeutic applications
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
NO20082699L (no) Immunoglobuliner
EP4556067A3 (de) Gem-disubstituierte piperidin-melanocortin subtyp-2-rezeptor (mc2r)-antagonisten und deren verwendungen
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2005051178A3 (en) Marker for neuromyelitis optica
WO2008045406A3 (en) COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
TW200732296A (en) Novel compounds
TW200615399A (en) Coating material for coating platinum material, platinum material having such coating material, and glass making apparatus
NO20065252L (no) Behandling av forstyrrelser
NO20060466L (no) Variable antibodies
EP1824498A4 (de) Verfahren und zusammensetzungen zur behandlung proliferativer zellkrankheiten
WO2004111089A3 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof